Skip to main navigation
Top
Skip to main content
Agios Logo Agios Logo
  • About Us

    About Us

    • Values
    • History
    • Leadership
    • Corporate Social Responsibility
    • Access to Medicines
    • News
      About Us
    • Values

    • History

    • Leadership

    • Corporate Social Responsibility

    • Access to Medicines

    • News

  • Genetically Defined Diseases

    Genetically Defined Diseases

    • Pyruvate Kinase Deficiency
    • Thalassemia
    • Sickle Cell Disease
    • Our Science
      Genetically Defined Diseases
    • Pyruvate Kinase Deficiency

    • Thalassemia

    • Sickle Cell Disease

    • Our Science

  • Pipeline

    Pipeline

  • Our Medicine

    Our Medicine

  • Patients & Partners

    Patients & Partners

    • Patients & Caregivers
      • Clinical Trials

      • Patient Resources

    • Healthcare Providers

      • Clinical Data Sharing

    • Partner Opportunities

        Patients & Partners
      • Patients & Caregivers

        • Clinical Trials

        • Patient Resources

      • Healthcare Providers

        • Clinical Data Sharing

      • Partner Opportunities

      • Investors

        Investors

        • News & Events
        • Stock Information
        • Corporate Governance
        • Financials
        • IR Resources

          Investors

        • News & Events

        • Stock Information

        • Corporate Governance

        • Financials

        • IR Resources

      • Inside Agios

        Inside Agios

        • Careers

        • Culture

        • Diversity

        • Commitment to Community

        • Benefits

          Inside Agios
        • Careers

        • Culture

        • Diversity

        • Commitment to Community

        • Benefits

      SEC Filing Details

      • Investors Overview
      • News & Events
        • Press Releases
        • Publications
        • Events & Presentations
      • Stock Information
      • Corporate Governance
        • Leadership
        • Board of Directors
        • Corporate Fact Sheet
        • Environment, Social and Governance (ESG) Report
      • Financials
        • SEC Filings
        • Annual Reports & Proxy
        • Quarterly Results
      • IR Resources
        • Investor FAQs
        • IR Contact
        • Information Request
        • Email Alerts

      SEC Filing Details

      Document Details

      Form
      10-Q
      Filing Date
      Aug 04, 2022
      Document Date
      Jun 30, 2022
      Form Description
      Quarterly report which provides a continuing view of a company's financial position
      Filing Group
      Quarterly Filings
      Company
      Agios Pharmaceuticals, Inc.
      Issuer
      AGIOS PHARMACEUTICALS, INC.

      Filing Formats

      iXBRL
      View HTML
      Download PDF
      Download DOC
      Download XLS

      XBRL

      XBRL Viewer
      EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
      EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
      EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
      EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
      EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
      XML - XBRL INSTANCE DOCUMENT
      • latest-earnings-call Latest Earnings Call View Replay
      • latest-form-10-k Latest Form 10-K View PDF
      • email-alerts Email Alerts Sign Up
      • corporate-fact-sheet Corporate Fact Sheet View PDF
      • corporate-responsibility Corporate Responsibility View PDF

      Connect with us on LinkedIn or follow us on Twitter as we push forward into changing the landscape for people with genetically defined diseases.

      LinkedIn logo Connect on LinkedIn
      Twitter logo Follow us our Twitter
      • Contact
      • About Us
      • Patients & Partners
      • Careers
      Agios Logo

      Agios Pharmaceuticals, Inc. © 2023

      All right reserved.

      • Cookies Preferences
      • Copyright Info
      • Compliance
      • Sitemap
      • Privacy Notice
      • Terms of Use